Productivity

Pharmacy

 

3rd term (2019-)

Original articles
  1. Hibino, M., Yamada, Y., Fujishita, N., Sato, Y., Maeki, M., Tokeshi, M., and Harashima, H. (2019) The use of a microfluidic device to encapsulate a poorly water-soluble drug CoQ10 in lipid nanoparticles and an attempt to regulate intracellular trafficking to reach mitochondria. J Pharm Sci [in press]
  2. Sato, Y., Hashiba, K., Sasaki, K., Maeki, M., Tokeshi, M., and Harashima, H. (2019) Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo. J Control Release 295, 140-152
  3. Masuda, H., Nakamura, T., Noma, Y., and Harashima, H. (2019) Application of BCG-CWS as a systemic adjuvant by using nanoparticulation technology. Mol Pharm 15, 5762-5771
  4. Abd Elwakil, M.M., Khalil, I.A., Elewa, Y.H.A., Kusumoto, K., Sato, Y., Shobaki, N., Kon, Y., and Harashima, H. (2019) Lung‐Endothelium‐Targeted Nanoparticles Based on a pH‐Sensitive Lipid and the GALA Peptide Enable Robust Gene Silencing and the Regression of Metastatic Lung Cancer. Advanced Functional Materials 29, Issue 18, 1807677

 

 

Review articles

 

 

Books

 

 

invited lectures, international

 

 

Presentation, international
  1. Haloho S, Nakamura T, Harashima H. Liposomal delivery of TLR3-adjuvant induces robust antitumor activity and diminishes the systemic toxicity following intravenous administration. Keystone Symposia Conference: Cancer Vaccines (January 20-24, 2019, Fairmont Hotel Vancouver, Vancouver, British Columbia, Canada)

 

 

 

2nd term (2014-2018)

Original articles
  1. Shobaki, N., Sato, Y., and Harashima, H. (2018) Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting. Int J Nanomedicine 13, 8395-8410
  2. Sakurai, Y., Hada, T., Kato, A., Hagino, Y., Mizumura, W., and Harashima, H. (2018) Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis. Mol Ther Oncolytics 11, 102-108
  3. Abbasi, S., Kajimoto, K., and Harashima, H. (2018) Critical parameters dictating efficiency of membrane-mediated drug transfer using nanoparticles. Int J Pharm 553, 398-407
  4. Sato, Y., Matsui, H., Sato, R., and Harashima, H. (2018) Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA. J Control Release 284, 179-187
  5. Kimura, N., Maeki, M., Sato, Y., Note, Y., Ishida, A., Tani, H., Harashima, H., and Tokeshi, M. (2018) Development of the iLiNP Device: Fine Tuning the Lipid Nanoparticle Size within 10 nm for Drug Delivery. ACS Omega 3, 5044-5051
  6. Nakamura, T., Yamada, K., Fujiwara, Y., Sato, Y., and Harashima, H. (2018) Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core. Mol Pharm 15, 2142-2150
  7. Khalil, I. A., and Harashima, H. (2018) An efficient PEGylated gene delivery system with improved targeting: Synergism between octaarginine and a fusogenic peptide. Int J Pharm 538, 179-187
  8. Khalil, I. A., Kimura, S., Sato, Y., and Harashima, H. (2018) Synergism between a cell penetrating peptide and a pH-sensitive cationic lipid in efficient gene delivery based on double-coated nanoparticles. J Control Release 275, 107-116
  9. Kajimoto, K., Katsumi, T., Nakamura, T., Kataoka, M., and Harashima, H. (2018) Liposome Microencapsulation for the Surface Modification and Improved Entrapment of Cytochrome c for Targeted Delivery. Journal of the American Oil Chemists’ Society 95, 101-109
  10. Sato, Y., Matsui, H., Yamamoto, N., Sato, R., Munakata, T., Kohara, M., and Harashima, H. (2017) Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus. J Control Release 266, 216-225
  11. Yamamoto, S., Sakurai, Y., and Harashima, H. (2017) Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption. Int J Pharm 536, 42-49
  12. Toriyabe, N., Sakurai, Y., Kato, A., Yamamoto, S., Tange, K., Nakai, Y., Akita, H., and Harahsima, H. (2017) The Delivery of Small Interfering RNA to Hepatic Stellate Cells Using a Lipid Nanoparticle Composed of a Vitamin A-Scaffold Lipid-Like Material. J Pharm Sci 106, 2046-2052
  13. Sakurai, Y., Hada, T., and Harashima, H. (2017) Scalable preparation of poly(ethylene glycol)-grafted siRNA-loaded lipid nanoparticles using a commercially available fluidic device and tangential flow filtration. J Biomater Sci Polym Ed 28, 1086-1096
  14. Maeki, M., Fujishima, Y., Sato, Y., Yasui, T., Kaji, N., Ishida, A., Tani, H., Baba, Y., Harashima, H., and Tokeshi, M. (2017) Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers. PLoS One 12, e0187962
  15. Sakurai, Y., Mizumura, W., Murata, M., Hada, T., Yamamoto, S., Ito, K., Iwasaki, K., Katoh, T., Goto, Y., Takagi, A., Kohara, M., Suga, H., and Harashima, H. (2017) Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting. Mol Pharm 14, 3290-3298
  16. Hashiba, K., Sato, Y., and Harashima, H. (2017) pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes. J Control Release 262, 239-246
  17. Santiwarangkool, S., Akita, H., Nakatani, T., Kusumoto, K., Kimura, H., Suzuki, M., Nishimura, M., Sato, Y., and Harashima, H. (2017) PEGylation of the GALA Peptide Enhances the Lung-Targeting Activity of Nanocarriers That Contain Encapsulated siRNA. J Pharm Sci 106, 2420-2427
  18. Yamada, Y., Munechika, R., Kawamura, E., Sakurai, Y., Sato, Y., and Harashima, H. (2017) Mitochondrial Delivery of Doxorubicin Using MITO-Porter Kills Drug-Resistant Renal Cancer Cells via Mitochondrial Toxicity. J Pharm Sci 106, 2428-2437
  19. Yamamoto, S., Kato, A., Sakurai, Y., Hada, T., and Harashima, H. (2017) Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles. J Control Release 251, 1-10
  20. Lee, S. H., Sato, Y., Hyodo, M., and Harashima, H. (2017) Size-Dependency of the Surface Ligand Density of Liposomes Prepared by Post-insertion. Biol Pharm Bull 40, 1002-1009
  21. Nakamura, T., Noma, Y., Sakurai, Y., and Harashima, H. (2017) Modifying Cationic Liposomes with Cholesteryl-PEG Prevents Their Aggregation in Human Urine and Enhances Cellular Uptake by Bladder Cancer Cells. Biol Pharm Bull 40, 234-237
  22. Warashina, S., Nakamura, T., Sato, Y., Fujiwara, Y., Hyodo, M., Hatakeyama, H., and Harashima, H. (2016) A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells. J Control Release 225, 183-191
  23. Hida, K., Maishi, N., Sakurai, Y., Hida, Y., and Harashima, H. (2016) Heterogeneity of tumor endothelial cells and drug delivery. Advanced drug delivery reviews 99, 140-147
  24. Sakurai, Y., Hada, T., Yamamoto, S., Kato, A., Mizumura, W., and Harashima, H. (2016) Remodeling of the Extracellular Matrix by Endothelial Cell-Targeting siRNA Improves the EPR-Based Delivery of 100nm Particles. Mol Ther 24, 2090-2099
  25. Nakamura, T., Kuroi, M., Fujiwara, Y., Warashina, S., Sato, Y., and Harashima, H. (2016) Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines. Sci Rep 6, 37849
  26. Shrivastava, G., Hyodo, M., Yoshimura, S. H., Akita, H., and Harashima, H. (2016) Identification of a Nucleoporin358-Specific RNA Aptamer for Use as a Nucleus-Targeting Liposomal Delivery System. Nucleic Acid Ther 26, 286-298
  27. Kibria, G., Hatakeyama, H., Sato, Y., and Harashima, H. (2016) Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors. Int J Pharm 509, 178-187
  28. Abbasi, S., Kajimoto, K., and Harashima, H. (2016) Elimination of the biphasic pharmacodynamics of 15d-PGJ2 by controlling its release from a nanoemulsion. Int J Nanomedicine 11, 2685-2694
  29. Sato, Y., Note, Y., Maeki, M., Kaji, N., Baba, Y., Tokeshi, M., and Harashima, H. (2016) Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery. J Control Release 229, 48-57
  30. Kajimoto, K., Suemitsu, E., Sato, Y., Sakurai, Y., and Harashima, H. (2016) Liver-Specific Silencing of Lipin1 Reduces Fat Mass as Well as Hepatic Triglyceride Biosynthesis in Mice. Biol Pharm Bull 39, 1653-1661
  31. Lee, S. H., Sato, Y., Hyodo, M., and Harashima, H. (2016) Topology of Surface Ligands on Liposomes: Characterization Based on the Terms, Incorporation Ratio, Surface Anchor Density, and Reaction Yield. Biol Pharm Bull 39, 1983-1994
  32. Sakurai, Y., Hada, T., and Harashima, H. (2016) Preparation of a Cyclic RGD: Modified Liposomal SiRNA Formulation for Use in Active Targeting to Tumor and Tumor Endothelial Cells. Methods Mol Biol 1364, 63-69
  33. Sato, Y., Harashima, H., and Kohara, M. (2016) A Multifunctional Envelope-Type Nano Device Containing a pH-Sensitive Cationic Lipid for Efficient Delivery of Short Interfering RNA to Hepatocytes In Vivo. Methods Mol Biol 1364, 71-78
  34. Yamamoto, N., Sato, Y., Munakata, T., Kakuni, M., Tateno, C., Sanada, T., Hirata, Y., Murakami, S., Tanaka, Y., Chayama, K., Hatakeyama, H., Hyodo, M., Harashima, H., and Kohara, M. (2015) Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection. J Hepatol 64, 547-555
  35. Tanoi, T., Tamura, T., Sano, N., Nakayama, K., Fukunaga, K., Zheng, Y. W., Akhter, A., Sakurai, Y., Hayashi, Y., Harashima, H., and Ohkohchi, N. (2015) Protecting liver sinusoidal endothelial cells suppresses apoptosis in acute liver damage. Hepatol Res 46, 697-706
  36. Sano, N., Tamura, T., Toriyabe, N., Nowatari, T., Nakayama, K., Tanoi, T., Murata, S., Sakurai, Y., Hyodo, M., Fukunaga, K., Harashima, H., and Ohkohchi, N. (2015) New drug delivery system for liver sinusoidal endothelial cells for ischemia-reperfusion injury. World J Gastroenterol 21, 12778-12786
  37. Sato, Y., Hatakeyama, H., Hyodo, M., and Harashima, H. (2015) Relationship Between the Physicochemical Properties of Lipid Nanoparticles and the Quality of siRNA Delivery to Liver Cells. Mol Ther 24, 788-795
  38. Matsui, H., Sato, Y., Hatakeyama, H., Akita, H., and Harashima, H. (2015) Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier. Int J Pharm 495, 171-178
  39. Nakamura, T., Miyabe, H., Hyodo, M., Sato, Y., Hayakawa, Y., and Harashima, H. (2015) Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. J Control Release 216, 149-157
  40. Akita, H., Noguchi, Y., Hatakeyama, H., Sato, Y., Tange, K., Nakai, Y., and Harashima, H. (2015) Molecular Tuning of a Vitamin E-Scaffold pH-Sensitive and Reductive Cleavable Lipid-like Material for Accelerated in Vivo Hepatic siRNA Delivery. ACS Biomaterials Science & Engineering 1, 834-844
  41. Hada, T., Sakurai, Y., and Harashima, H. (2015) Optimization of a siRNA Carrier Modified with a pH-Sensitive Cationic Lipid and a Cyclic RGD Peptide for Efficiently Targeting Tumor Endothelial Cells. Pharmaceutics 7, 320-333
  42. Calabuig-Navarro, V., Yamauchi, J., Lee, S., Zhang, T., Liu, Y. Z., Sadlek, K., Coudriet, G. M., Piganelli, J. D., Jiang, C. L., Miller, R., Lowe, M., Harashima, H., and Dong, H. H. (2015) Forkhead Box O6 (FoxO6) Depletion Attenuates Hepatic Gluconeogenesis and Protects against Fat-induced Glucose Disorder in Mice. J Biol Chem 290, 15581-15594
  43. Akita, H., Fujiwara, T., Santiwarangkool, S., Hossen, N., Kajimoto, K., El-Sayed, A., Tabata, Y., and Harashima, H. (2015) Transcytosis-Targeting Peptide: A Conductor of Liposomal Nanoparticles through the Endothelial Cell Barrier. Small 12, 1212-1221
  44. Maeki, M., Saito, T., Sato, Y., Yasui, T., Kaji, N., Ishida, A., Tani, H., Baba, Y., Harashima, H., and Tokeshi, M. (2015) A strategy for synthesis of lipid nanoparticles using microfluidic devices with a mixer structure. RSC Advances 5, 46181-46185
  45. Sakurai, Y., Matsuda, T., Hada, T., and Harashima, H. (2015) Efficient Packaging of Plasmid DNA Using a pH Sensitive Cationic Lipid for Delivery to Hepatocytes. Biol Pharm Bull 38, 1185-1191
  46. Sato, S., Li, K., Kameyama, T., Hayashi, T., Ishida, Y., Murakami, S., Watanabe, T., Iijima, S., Sakurai, Y., Watashi, K., Tsutsumi, S., Sato, Y., Akita, H., Wakita, T., Rice, C. M., Harashima, H., Kohara, M., Tanaka, Y., and Takaoka, A. (2014) The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity 42, 123-132
  47. Sakurai, Y., Hatakeyama, H., Akita, H., and Harashima, H. (2014) Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas. Mol Pharm 11, 2713-2719
  48. Tamaru, M., Akita, H., Kajimoto, K., Sato, Y., Hatakeyama, H., and Harashima, H. (2014) An apolipoprotein E modified liposomal nanoparticle: ligand dependent efficiency as a siRNA delivery carrier for mouse-derived brain endothelial cells. Int J Pharm 465, 77-82
  49. Watanabe, T., Hatakeyama, H., Matsuda-Yasui, C., Sato, Y., Sudoh, M., Takagi, A., Hirata, Y., Ohtsuki, T., Arai, M., Inoue, K., Harashima, H., and Kohara, M. (2014) In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus. Sci Rep 4, 4750
  50. Hossen, M. N., Kajimoto, K., Tatsumi, R., Hyodo, M., and Harashima, H. (2014) Comparative assessments of crucial factors for a functional ligand-targeted nanocarrier. J Drug Target 22, 600-609
  51. Kajimoto, K., Minami, Y., and Harashima, H. (2014) Cytoprotective role of the fatty acid binding protein 4 against oxidative and endoplasmic reticulum stress in 3T3-L1 adipocytes. FEBS Open Bio 4, 602-610
  52. Miyabe, H., Hyodo, M., Nakamura, T., Sato, Y., Hayakawa, Y., and Harashima, H. (2014) A new adjuvant delivery system ‘cyclic di-GMP/YSK05 liposome’ for cancer immunotherapy. J Control Release 184, 20-27
  53. Ikeda, Y., Tsuchiya, H., Hama, S., Kajimoto, K., and Kogure, K. (2014) Resistin regulates the expression of plasminogen activator inhibitor-1 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 448, 129-133
  54. Hayashi, Y., Suemitsu, E., Kajimoto, K., Sato, Y., Akhter, A., Sakurai, Y., Hatakeyama, H., Hyodo, M., Kaji, N., Baba, Y., and Harashima, H. (2014) Hepatic Monoacylglycerol O-acyltransferase 1 as a Promising Therapeutic Target for Steatosis, Obesity, and Type 2 Diabetes. Mol Ther Nucleic Acids 3, e154
  55. Akhter, A., Hayashi, Y., Sakurai, Y., Ohga, N., Hida, K., and Harashima, H. (2014) Ligand density at the surface of a nanoparticle and different uptake mechanism: two important factors for successful siRNA delivery to liver endothelial cells. International journal of pharmaceutics 475, 227-237
  56. Ara, M. N., Hyodo, M., Ohga, N., Akiyama, K., Hida, K., Hida, Y., Shinohara, N., and Harashima, H. (2014) Identification and expression of troponin T, a new marker on the surface of cultured tumor endothelial cells by aptamer ligand. Cancer medicine 3, 825-834
  57. Ara, M. N., Matsuda, T., Hyodo, M., Sakurai, Y., Hatakeyama, H., Ohga, N., Hida, K., and Harashima, H. (2014) An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells. Biomaterials 35, 7110-7120
  58. Sakurai, Y., Hatakeyama, H., Sato, Y., Hyodo, M., Akita, H., Ohga, N., Hida, K., and Harashima, H. (2014) RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system. Journal of controlled release : official journal of the Controlled Release Society 173, 110-118
  59. Ara, M. N., Matsuda, T., Hyodo, M., Sakurai, Y., Ohga, N., Hida, K., and Harashima, H. (2014) Construction of an aptamer modified liposomal system targeted to tumor endothelial cells. Biological & pharmaceutical bulletin 37, 1742-1749
  60. Kibria, G., Hatakeyama, H., Akiyama, K., Hida, K., and Harashima, H. (2014) Comparative study of the sensitivities of cancer cells to doxorubicin, and relationships between the effect of the drug-efflux pump P-gp. Biological & pharmaceutical bulletin 37, 1926-1935
  61. Akita, H., Ishiba, R., Togashi, R., Tange, K., Nakai, Y., Hatakeyama, H., and Harashima, H. (2014) A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma. J Control Release 200, 97-105
  62. Hatakeyama, H., Murata, M., Sato, Y., Takahashi, M., Minakawa, N., Matsuda, A., and Harashima, H. (2014) The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. J Control Release 173, 43-50
  63. Shrivastava, G., Hyodo, M., Ara, M. N., and Harashima, H. (2014) The screening of RNA aptamers specific for carbonic anhydrase I using the Systematic Evolution of Ligands by an Exponential Enrichment Method (SELEX). Nucleosides Nucleotides Nucleic Acids 33, 697-708
  64. Tamaru, M., Akita, H., Nakatani, T., Kajimoto, K., Sato, Y., Hatakeyama, H., and Harashima, H. (2014) Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain. Int J Nanomedicine 9, 4267-4276
  65. Tawaraya, Y., Hyodo, M., Ara, M. N., Yamada, Y., and Harashima, H. (2014) RNA aptamers for targeting mitochondria using a mitochondria-based SELEX method. Biol Pharm Bull 37, 1411-1415
  66. Hama, S., Kimura, Y., Mikami, A., Shiota, K., Toyoda, M., Tamura, A., Nagasaki, Y., Kanamura, K., Kajimoto, K., and Kogure, K. (2013) Electric stimulus opens intercellular spaces in skin. J Biol Chem 289, 2450-2456
  67. Kibria, G., Hatakeyama, H., and Harashima, H. (2013) Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res 37, 4-15

 

 

Review articles
  1. Khalil, I. A., Yamada, Y., and Harashima, H. (2018) Optimization of siRNA delivery to target sites: issues and future directions. Expert opinion on drug delivery 15, 1053-1065
  2. Maeki, M., Kimura, N., Sato, Y., Harashima, H., and Tokeshi, M. (2018) Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems. Advanced drug delivery reviews 128, 84-100
  3. Nichols, J. W., Sakurai, Y., Harashima, H., and Bae, Y. H. (2017) Nano-sized drug carriers: Extravasation, intratumoral distribution, and their modeling. Journal of controlled release : official journal of the Controlled Release Society 267, 31-46
  4. Sato, Y., Sakurai, Y., Kajimoto, K., Nakamura, T., Yamada, Y., Akita, H., and Harashima, H. (2017) Innovative Technologies in Nanomedicines: From Passive Targeting to Active Targeting/From Controlled Pharmacokinetics to Controlled Intracellular Pharmacokinetics. Macromolecular bioscience 17
  5. Sato, Y., Nakamura, T., Yamada, Y., and Harashima, H. (2016) Development of a multifunctional envelope-type nano device and its application to nanomedicine. Journal of controlled release : official journal of the Controlled Release Society 244, 194-204
  6. Tanaka, H., Sato, Y., Harashima, H., and Akita, H. (2016) Cellular environment-responsive nanomaterials for use in gene and siRNA delivery: molecular design for biomembrane destabilization and intracellular collapse. Expert opinion on drug delivery 13, 1015-1027
  7. Sakurai, Y., Kajimoto, K., and Harashima, H. (2015) Anti-angiogenic nanotherapy via active targeting systems to tumors and adipose tissue vasculature. Biomaterials science 3, 1253-1265
  8. Hayashi, Y., Hatakeyama, H., Kajimoto, K., Hyodo, M., Akita, H., and Harashima, H. (2015) Multifunctional Envelope-Type Nano Device: Evolution from Nonselective to Active Targeting System. Bioconjugate chemistry 26, 1266-1276
  9. Sakurai, Y., Kajimoto, K., Hatakeyama, H., and Harashima, H. (2015) Advances in an active and passive targeting to tumor and adipose tissues. Expert opinion on drug delivery 12, 41-52
  10. Hyodo, M., Sakurai, Y., Akita, H., and Harashima, H. (2014) “Programmed packaging” for gene delivery. Journal of controlled release : official journal of the Controlled Release Society 193, 316-323
  11. Kajimoto, K., Sato, Y., Nakamura, T., Yamada, Y., and Harashima, H. (2014) Multifunctional envelope-type nano device for controlled intracellular trafficking and selective targeting in vivo. Journal of controlled release : official journal of the Controlled Release Society 190, 593-606
  12. Kibria, G., Hatakeyama, H., and Harashima, H. (2014) Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Archives of pharmacal research 37, 4-15

 

 

Books
  1. Sato Y, Nakamura T, Yamada Y, Akita H, Harashima H. “Multifunctional Enveloped Nanodevices (MENDs).” In L. Huang (Ed.), Non-Viral Vectors for Gene Therapy: Lipid- and Polymer-based Gene Transfer. Academic Press. (2014) 139-204.

 

 

Invited lecture, international
  1. Ikramy A. Khalil, “Gene Therapy between Reality and Future”. Ethics in Drug Manufacturing Conference, Islamic Organization for Medical Sciences. Dec 9-11, 2018, Kuwait city, Kuwait.
  2. Hideyoshi Harashima, Multifunctional Envelope-type Nano Device for Gene Delivery: Concept and Application for Nanomedicine, 13th France-Japan Drug Delivery System Symposium, October 22, Ise-Shima, Mie, Japan
  3. Hideyoshi Harashima, Multifunctional Envelope-type Nano Device for Gene Delivery: Concept and Clinical Application for Nanomedicine, The 19th International Pharmaceutical Technology Symposium, September 17th, 2018, Antalya, Turkey
  4. Hideyoshi Harashima, Multifunctional Envelope-type Nano Device for Nanomedicine, The 5th International Biomaterials Symposium, August 25th, 2018, CHanchun, China
  5. Hideyoshi Harashima, Controlled Intracellular Trafficking and Selective Tissue Targeting by Multifunctional Envelope-type Nano Device for Nucleic Acid Nanomedicine, Scientific Session: Nucleic Acid Delivery, The 45th CRS Annual Meeting & Exposition, July 23, 2018, New York, USA
  6. Hideyoshi Harashima、Multifunctional Envelope-type Nano Device for Nanomedicine AsiaTIDES: Oligonucleotide & Peptide Therapeutics、February 21, 2017、The Westin Miyako Kyoto, Japan
  7. Harashima H. “Multifunctional lipid-based systems for drug and gene delivery” 20th International Symposium on Microencapsulation, October 1, 2015 (Boston, USA)
  8. Harashima H. “Activities of Education and Researches in Faculty of Pharmaceutical Sciences” The UP-HU Joint Workshop for Academic Exchange, September 17th, 2015 (Pretoria, South Africa)
  9. Harashima H. “Multifunctional envelope-type nano device for gene delivery: Concept and application for Nanomedicine” International Seminar on Pharmaceutics 2015, August 4, 2015 (Bandung, Indonesia)
  10. Harashima H. “Multifunctional envelope-type nano device for gene delivery: Concept and application for Nanomedicine” Biomaterials International 2015, June 2, 2015 (Kenting, Taiwan)
  11. Harashima H. “Multifunctional envelope-type nano device for gene delivery: Concept and application for Nanomedicine” The 5th Asian Biomaterials Congress, May 7th, 2015, (Taipei, Taiwan)
  12. Harashima H. “Multifunctional Envelope-type Nano Device, for Nanomedicine” Workshop on Global Future Healthcare, on Materials Science and Engineering, Jointly Organized by Nanyang Technological University (NTU) and Hokkaido University, October 21, 2014 (Singapore)
  13. Harashima H. “Multifunctional Envelope-type Nano Device for gene delivery: Concept and application for Nanomedicine” The 11th France – Japan DDS Symposium Recent Achievements and Further Challenges, in Drug Delivery Research, October 7th, 2014, (Awaji, Japan)
  14. Harashima H. “Multifunctional envelope-type nano device for gene delivery: Concept and application for Nanomedicine” Current and Future Aspect of Drug Delivery, August 8th, 2014 (Taipei, Taiwan)
  15. Harashima H. “MITO-Porter: Membrane-type nano device for mitochondrial drug delivery via membrane fusions” Euromit 2014, June 19th, 2014 (Tampere, Finland)
  16. Harashima H. “Breakthrough technology based on controlled intracellular trafficking of functional nucleic acids with MEND.” 5th FIP Pharmaceutical Sciences World Congress (PSWC), Apr 15, 2014 (Melbourne, Australia)

 

 

Presentation, international
  1. Yamada Y, Munechika R, Sato Y, Sakurai Y, Harashima H. Validation of a cancer therapeutic strategy by the mitochondrial delivery of anticancer drugs using a MITO-Porter system. 2018 Annual Meeting & Exposition of the Controlled Release Society. July 22-24, 2018, New York NY, USA.
  2. Shobaki N, Sato Y, Harashima H. “Targeted delivery of siRNAs by manipulating acid dissociation constant of lipid nanoparticles.” The 5th International Life Science Symposium for Young Scientists, Oct 7, 2017, Hokkaido University Conference Hall, Sapporo, Japan
  3. Takahashi N, Nakamura T, Sato Y, Hyodo M, Hayakawa Y, Harashima H. Cancer immunotherapy by STING ligand loaded lipid nanoparticles. The 36th Sapporo International Cancer Symposium (Royton Sapporo, Sapporo, Hokkaido, Japan, June 22-24, 2017).
  4. Shobaki N, Sato Y, Hashiba K, Harashima H. “Development of siRNA-loaded lipid nanoparticles targeting tumor-associated macrophages for cancer immunetherapy.” The 36th Sapporo International Cancer Symposium, Jun 22-24, 2017, Royton Sapporo, Sapporo, Japan
  5. Nakamura T, Miyabe H, Hyodo M, Sato Y, Hayakawa Y, Harashima H. “STING ligand loaded lipid nanoparticles enhance cancer immunotherapy.” 3rd International Conference on Biomaterials Science, 28-30th Nov, 2016 (Ito Hall, Ito International Research Center, The University of Tokyo, Tokyo, Japan).
  6. Shobaki N, Sato Y, Harashima H. “Optimizing siRNA delivery using specific multifunctional envelope-type nanodevice for liver sinusoidal endothelial cells.” Asian conference on nanoscience and nanotechnology, AsiaNANO 2016: Asian Conference on Nanoscience and Nanotechnology, 10-13th Oct, 2016 (Sapporo Convention Center, Sapporo, Japan)
  7. Sato Y, Hatakeyama H, Hyodo M, Yamamoto N, Kohara M, Harashima H. “Development of siRNA delivery system for the treatment of hepatitis B viral infection” The 18th Hokkaido University – Seoul National University Joint Sympojium, 27th Nov, 2015 (Seoul, Korea).
  8. Matsui H, Sato Y, Harashima H. “Improvement of therapeutic window of the liver-targeting siRNA delivery” The 18th Hokkaido University – Seoul National University Joint Sympojium, 27th Nov, 2015 (Seoul, Korea).
  9. Note Y, Sato Y, Maeki M, Tokeshi M, Harashima H. “Elucidation of the physicochemical properties and potency for siRNA delivery of the siRNA-loaded small-sized nanoparticles” The 18th Hokkaido University – Seoul National University Joint Sympojium, 27th Nov, 2015 (Seoul, Korea).
  10. Sakurai Y, Mizumura W, Murata M, Sato Y, Harashima H. “Active targeting to tumor tissue via optimized ligand modification” The 18th Hokkaido University – Seoul National University Joint Sympojium, 27th Nov, 2015 (Seoul, Korea).
  11. Hada T, Sakurai Y, Yamamoto S, Harashima H. “Improvement of Nanoparticles Intratumoral Distribution via siRNA-mediated Gene Suppression in Vascular Endothelial Cells” The 18th Hokkaido University – Seoul National University Joint Sympojium, 27th Nov, 2015 (Seoul, Korea).
  12. Mahara N, Kajimoto K, Harashima H. “Elucidation of endocytosis mechanisms of prohibitin-mediated pathway” The 18th Hokkaido University – Seoul National University Joint Sympojium, 27th Nov, 2015 (Seoul, Korea).
  13. Abbasi S, Kajimoto K, Harashima H. “Nano-Emulsion for the control of 15d-PGJ2 biphasic pharmacodynamics” The 18th Hokkaido University – Seoul National University Joint Sympojium, 27th Nov, 2015 (Seoul, Korea).
  14. Sarochin Santiwarangkool, Kenji Kusumoto, Hidetaka Akita, Hideyoshi Harashima. “Development of the lung-targeting nanoparrier.” The 18th Hokkaido University-Seoul National University Joint Symposium, November 27th, 2015 (Seoul, Korea)
  15. Jun Yamauchi. “Novel therapeutic target for Type 2 diabetes based on molecular mechanisms.” he 17th Hokkaido University-Seoul National University Joint Symposium, November 28th, 2014 (Sapporo, Japan,)
  16. Mahmuda Nargis. “Development of an adipose vasculature-targeted nanocarrier utilizing a novel DNA aptamer.” The 17th Hokkaido University-Seoul National University Joint Symposium, November 28th, 2014 (Sapporo, Japan,)
  17. Yu Sakurai. “Construction of a ligand-mediated siRNA delivery system to tumor endothelial cells.” The 17th Hokkaido University-Seoul National University Joint Symposium, November 28th, 2014 (Sapporo, Japan,)

 

 

 

1st term (2009-2013)

Original articles
  1. Takahashi, M., Yamada, N., Hatakeyama, H., Murata, M., Sato, Y., Minakawa, N., Harashima, H., and Matsuda, A. (2013) In vitro optimization of 2′-OMe-4′-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle. Nucleic acids research 41, 10659-10667
  2. Akita, H., Ishii, S., Miura, N., Shaheen, S. M., Hayashi, Y., Nakamura, T., Kaji, N., Baba, Y., and Harashima, H. (2013) A DNA microarray-based analysis of immune-stimulatory and transcriptional responses of dendritic cells to KALA-modified nanoparticles. Biomaterials 34, 8979-8990
  3. Ikeda, Y., Tsuchiya, H., Hama, S., Kajimoto, K., and Kogure, K. (2013) Resistin affects lipid metabolism during adipocyte maturation of 3T3-L1 cells. The FEBS journal 280, 5884-5895
  4. Kawamura, E., Yamada, Y., Yasuzaki, Y., Hyodo, M., and Harashima, H. (2013) Intracellular observation of nanocarriers modified with a mitochondrial targeting signal peptide. Journal of bioscience and bioengineering 116, 634-637
  5. Hossen, N., Kajimoto, K., Akita, H., Hyodo, M., and Harashima, H. (2013) A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. Journal of controlled release : official journal of the Controlled Release Society 171, 104-112
  6. Kusumoto, K., Akita, H., Ishitsuka, T., Matsumoto, Y., Nomoto, T., Furukawa, R., El-Sayed, A., Hatakeyama, H., Kajimoto, K., Yamada, Y., Kataoka, K., and Harashima, H. (2013) Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium. ACS nano 7, 7534-7541
  7. Akita, H., Ishiba, R., Hatakeyama, H., Tanaka, H., Sato, Y., Tange, K., Arai, M., Kubo, K., and Harashima, H. (2013) A neutral envelope-type nanoparticle containing pH-responsive and SS-cleavable lipid-like material as a carrier for plasmid DNA. Advanced healthcare materials 2, 1120-1125
  8. Sakurai, Y., Hatakeyama, H., Sato, Y., Hyodo, M., Akita, H., and Harashima, H. (2013) Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. Molecular therapy : the journal of the American Society of Gene Therapy 21, 1195-1203
  9. Hossen, M. N., Kajimoto, K., Akita, H., Hyodo, M., Ishitsuka, T., and Harashima, H. (2013) Therapeutic assessment of cytochrome C for the prevention of obesity through endothelial cell-targeted nanoparticulate system. Molecular therapy : the journal of the American Society of Gene Therapy 21, 533-541
  10. Yamada, Y., Hashida, M., Hayashi, Y., Tabata, M., Hyodo, M., Ara, M. N., Ohga, N., Hida, K., and Harashima, H. (2013) An approach to transgene expression in liver endothelial cells using a liposome-based gene vector coated with hyaluronic acid. Journal of pharmaceutical sciences 102, 3119-3127
  11. Kibria, G., Hatakeyama, H., Ohga, N., Hida, K., and Harashima, H. (2013) The effect of liposomal size on the targeted delivery of doxorubicin to Integrin alphavbeta3-expressing tumor endothelial cells. Biomaterials 34, 5617-5627
  12. Toriyabe, N., Hayashi, Y., and Harashima, H. (2013) The transfection activity of R8-modified nanoparticles and siRNA condensation using pH sensitive stearylated-octahistidine. Biomaterials 34, 1337-1343
  13. Akhter, A., Hayashi, Y., Sakurai, Y., Ohga, N., Hida, K., and Harashima, H. (2013) A liposomal delivery system that targets liver endothelial cells based on a new peptide motif present in the ApoB-100 sequence. International journal of pharmaceutics 456, 195-201
  14. Kajimoto, K., Takayanagi, S., Sasaki, S., Akita, H., and Harashima, H. (2012) RNA interference-based silencing reveals the regulatory role of fatty acid-binding protein 4 in the production of IL-6 and vascular endothelial growth factor in 3T3-L1 adipocytes. Endocrinology 153, 5629-5636
  15. Sato, Y., Hatakeyama, H., Sakurai, Y., Hyodo, M., Akita, H., and Harashima, H. (2012) A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. Journal of controlled release : official journal of the Controlled Release Society 163, 267-276
  16. Hayashi, Y., Mizuno, R., Ikramy, K. A., Akita, H., and Harashima, H. (2012) Pretreatment of hepatocyte growth factor gene transfer mediated by octaarginine peptide-modified nanoparticles ameliorates LPS/D-galactosamine-induced hepatitis. Nucleic acid therapeutics 22, 360-363
  17. Hossen, M. N., Kajimoto, K., Akita, H., Hyodo, M., and Harashima, H. (2012) Vascular-targeted nanotherapy for obesity: unexpected passive targeting mechanism to obese fat for the enhancement of active drug delivery. Journal of controlled release : official journal of the Controlled Release Society 163, 101-110
  18. Hayashi, Y., Noguchi, Y., and Harashima, H. (2012) Non-linear pharmacokinetics of octaarginine-modified lipid nanoparticles: barriers from in vitro to in vivo. Journal of controlled release : official journal of the Controlled Release Society 161, 757-762
  19. Takahashi, M., Nagai, C., Hatakeyama, H., Minakawa, N., Harashima, H., and Matsuda, A. (2012) Intracellular stability of 2′-OMe-4′-thioribonucleoside modified siRNA leads to long-term RNAi effect. Nucleic acids research 40, 5787-5793
  20. Takara, K., Hatakeyama, H., Kibria, G., Ohga, N., Hida, K., and Harashima, H. (2012) Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. Journal of controlled release : official journal of the Controlled Release Society 162, 225-232
  21. Ara, M. N., Hyodo, M., Ohga, N., Hida, K., and Harashima, H. (2012) Development of a novel DNA aptamer ligand targeting to primary cultured tumor endothelial cells by a cell-based SELEX method. PloS one 7, e50174
  22. Kigasawa, K., Miyashita, M., Kajimoto, K., Kanamura, K., Harashima, H., and Kogure, K. (2012) Efficient intradermal delivery of superoxide dismutase using a combination of liposomes and iontophoresis for protection against UV-induced skin damage. Biological & pharmaceutical bulletin 35, 781-785
  23. Khalil, I. A., Hayashi, Y., Mizuno, R., and Harashima, H. (2011) Octaarginine- and pH sensitive fusogenic peptide-modified nanoparticles for liver gene delivery. Journal of controlled release : official journal of the Controlled Release Society 156, 374-380
  24. Hayashi, Y., Yamauchi, J., Khalil, I. A., Kajimoto, K., Akita, H., and Harashima, H. (2011) Cell penetrating peptide-mediated systemic siRNA delivery to the liver. International journal of pharmaceutics 419, 308-313
  25. Abe, N., Abe, H., Nagai, C., Harada, M., Hatakeyama, H., Harashima, H., Ohshiro, T., Nishihara, M., Furukawa, K., Maeda, M., Tsuneda, S., and Ito, Y. (2011) Synthesis, structure, and biological activity of dumbbell-shaped nanocircular RNAs for RNA interference. Bioconjugate chemistry 22, 2082-2092
  26. Hatakeyama, H., Ito, E., Yamamoto, M., Akita, H., Hayashi, Y., Kajimoto, K., Kaji, N., Baba, Y., and Harashima, H. (2011) A DNA microarray-based analysis of the host response to a nonviral gene carrier: a strategy for improving the immune response. Molecular therapy : the journal of the American Society of Gene Therapy 19, 1487-1498
  27. Sakurai, Y., Hatakeyama, H., Sato, Y., Akita, H., Takayama, K., Kobayashi, S., Futaki, S., and Harashima, H. (2011) Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Biomaterials 32, 5733-5742
  28. Hatakeyama, H., Akita, H., Ito, E., Hayashi, Y., Oishi, M., Nagasaki, Y., Danev, R., Nagayama, K., Kaji, N., Kikuchi, H., Baba, Y., and Harashima, H. (2011) Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials 32, 4306-4316
  29. Kibria, G., Hatakeyama, H., and Harashima, H. (2011) A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system. International journal of pharmaceutics 412, 106-114
  30. Kigasawa, K., Kajimoto, K., Nakamura, T., Hama, S., Kanamura, K., Harashima, H., and Kogure, K. (2011) Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society 150, 256-265
  31. Kajimoto, K., Yamamoto, M., Watanabe, M., Kigasawa, K., Kanamura, K., Harashima, H., and Kogure, K. (2011) Noninvasive and persistent transfollicular drug delivery system using a combination of liposomes and iontophoresis. International journal of pharmaceutics 403, 57-65
  32. Ikeda, Y., Hama, S., Kajimoto, K., Okuno, T., Tsuchiya, H., and Kogure, K. (2011) Quantitative comparison of adipocytokine gene expression during adipocyte maturation in non-obese and obese rats. Biological & pharmaceutical bulletin 34, 865-870
  33. Toriyabe, N., Hayashi, Y., Hyodo, M., and Harashima, H. (2011) Synthesis and evaluation of stearylated hyaluronic acid for the active delivery of liposomes to liver endothelial cells. Biological & pharmaceutical bulletin 34, 1084-1089
  34. Kibria, G., Hatakeyama, H., Ohga, N., Hida, K., and Harashima, H. (2011) Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. Journal of controlled release : official journal of the Controlled Release Society 153, 141-148
  35. Hossen, M. N., Kajimoto, K., Akita, H., Hyodo, M., Ishitsuka, T., and Harashima, H. (2010) Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue. Journal of controlled release : official journal of the Controlled Release Society 147, 261-268
  36. Ukawa, M., Akita, H., Masuda, T., Hayashi, Y., Konno, T., Ishihara, K., and Harashima, H. (2010) 2-Methacryloyloxyethyl phosphorylcholine polymer (MPC)-coating improves the transfection activity of GALA-modified lipid nanoparticles by assisting the cellular uptake and intracellular dissociation of plasmid DNA in primary hepatocytes. Biomaterials 31, 6355-6362
  37. Tamaru, M., Akita, H., Fujiwara, T., Kajimoto, K., and Harashima, H. (2010) Leptin-derived peptide, a targeting ligand for mouse brain-derived endothelial cells via macropinocytosis. Biochemical and biophysical research communications 394, 587-592
  38. Hayashi, Y., Kajimoto, K., Iida, S., Sato, Y., Mizufune, S., Kaji, N., Kamiya, H., Baba, Y., and Harashima, H. (2010) DNA microarray analysis of whole blood cells and insulin-sensitive tissues reveals the usefulness of blood RNA profiling as a source of markers for predicting type 2 diabetes. Biological & pharmaceutical bulletin 33, 1033-1042
  39. Sato, Y., Hatakeyama, H., and Harashima, H. (2010) Ornithine and tryptophan analogs as efficient polycations for short interference RNA delivery to tumor cells. Biological & pharmaceutical bulletin 33, 1246-1249
  40. Takara, K., Hatakeyama, H., Ohga, N., Hida, K., and Harashima, H. (2010) Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. International journal of pharmaceutics 396, 143-148
  41. Kajimoto, K., Hossen, M. N., Hida, K., Ohga, N., Akita, H., Hyodo, M., Hida, Y., and Harashima, H. (2010) Isolation and culture of microvascular endothelial cells from murine inguinal and epididymal adipose tissues. Journal of immunological methods 357, 43-50
  42. Yamauchi, J., Hayashi, Y., Kajimoto, K., Akita, H., and Harashima, H. (2010) Comparison between a multifunctional envelope-type nano device and lipoplex for delivery to the liver. Biological & pharmaceutical bulletin 33, 926-929
  43. Hatakeyama, H., Ito, E., Akita, H., Oishi, M., Nagasaki, Y., Futaki, S., and Harashima, H. (2009) A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. Journal of controlled release : official journal of the Controlled Release Society 139, 127-132
  44. Akita, H., Kudo, A., Minoura, A., Yamaguti, M., Khalil, I. A., Moriguchi, R., Masuda, T., Danev, R., Nagayama, K., Kogure, K., and Harashima, H. (2009) Multi-layered nanoparticles for penetrating the endosome and nuclear membrane via a step-wise membrane fusion process. Biomaterials 30, 2940-2949
  45. Sakurai, Y., Hatakeyama, H., Akita, H., Oishi, M., Nagasaki, Y., Futaki, S., and Harashima, H. (2009) Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system. Biological & pharmaceutical bulletin 32, 928-932

 

 

Review articles
  1. El-Sayed, A., Futaki, S., and Harashima, H. (2009) Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. The AAPS journal 11, 13-22
  2. Hatakeyama, H., Akita, H., and Harashima, H. (2011) A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Advanced drug delivery reviews 63, 152-160
  3. Hatakeyama, H., Akita, H., and Harashima, H. (2013) The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biological & pharmaceutical bulletin 36, 892-899
  4. Hatakeyama, H., Akita, H., Kogure, K., and Harashima, H. (2010) A novel nonviral gene delivery system: multifunctional envelope-type nano device. Advances in biochemical engineering/biotechnology 119, 197-230
  5. Kajimoto, K., Hossen, M. N., and Harashima, H. (2013) Antiangiogenic nanotherapy for the control of obesity. Nanomedicine 8, 671-673
  6. Mudhakir, D., and Harashima, H. (2009) Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus. The AAPS journal 11, 65-77
  7. Nakamura, T., Akita, H., Yamada, Y., Hatakeyama, H., and Harashima, H. (2012) A multifunctional envelope-type nanodevice for use in nanomedicine: concept and applications. Accounts of chemical research 45, 1113-1121
  8. Sato, Y., Hatakeyama, H., Hyodo, M., Akita, H., and Harashima, H. (2012) [Development of an efficient short interference RNA (siRNA) delivery system with a new pH-sensitive cationic lipid]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 132, 1355-1363

 

 

Books
  1. Akita H, Hatakeyama H, Khalil IA, Yamada Y, Harashima H. “Delivery of Nucleic Acids and Gene Delivery.” Comprehensive Biomaterials (In: DucheyneＰ, Healy KE, Hutmacher DW, Grainger DW, Kirkpatrick CJ (eds.), Elsevier) 4: pp411-444, 2011.
  2. H. Hatakeyama, H. Akita, K. Kogure and H. Harashima. A Novel Nonviral Gene Delivery System: Multifunctional Envelope-type Nano Device p.197-230. Advances in Biochemical Engineering/Biotechnology 119 Nano/Micro Biotechnology, Series Editor T. Scheper, Volume Editors I. Endo and T. Nagamune, Springer (2010)

 

 

Invited lecture, international
  1. Kajimoto K. “New Approach in Obesity Therapy via a Vascular-targeted Nanoparticulate System.” IBC’s 6th Annual AsiaTIDES, 26th February, 2014 (Sheraton Miyako Hotel, Tokyo)
  2. Kajimoto K. “Nanotherapy for Control of Obesity.” The 16th Hokkaido University-Seoul National University Joint Symposium, December 13, 2013 (Seoul, Korea)
  3. Hyodo M. “Investigation of tumor endothelial cell targeting aptamer and its application for drug delivery.” The 16th Hokkaido University-Seoul National University Joint Symposium, December 13, 2013 (Seoul, Korea)
  4. Harashima H. “Contribution to Regulatory Sciences from Academia in Nanomedicine.” The 4th Asia Pacific Pharmacy Education Workshop, 24th-26th November, 2013 (Tokyo)
  5. Harashima H. “Multifunctional Envelope-type Nano Device for non-viral gene delivery: Concept and Application for Nanomedicine.” The 4th International Advanced Biomaterials Symposium 2013, 30th September, 2013 (Changchun, China)
  6. Harashima H. “Multifunctional Envelope-type Nano Device for non-viral gene delivery: Concept and application for Nanomedicine, Individualized Pharmaceutics for Optimized Drug Delivery.” Memorial Symposium for Professor Chan-Koo Shim, July 11, 2013, (Seoul, Korea)
  7. Harashima H. “Multifunctional Envelope-type Nano Device for non-viral gene delivery.” Concept and application for Nanomedicine, March 19-22, 2013, (Tsukuba)
  8. Harashima H. “Multifunctional Envelope-type Nano Device for Nanomedicine.” The 16th International Symposium on Recent Advances in Drug Delivery System, 4th February, 2013 (Utah, USA)
  9. Harashima H. “Multifunctional Envelope-type Nano Device for Nanomedicine.” The 1st IBN International Symposium, Nanosystems for Biomedical Applications, 11th January, 2013 (Singapore)
  10. Hayashi Y. “Identifying therapeutic targets for type 2 diabetes in combination with a DNA microarray and the non-viral in vivo delivery of siRNA.” The 15th Hokkaido University – Seoul National University Joint Sympojium, 7th Dec, 2012 (Sapporo).
  11. Harashima H. “Multifunctional Envelope-type Nano Device as gene delivery system for Nanomedicine.” The 10th France – Japan DDS Symposium, 11th October, 2012, (Amsterdam, Netherland)
  12. Harashima H. “Breakthrough Technologies in Gene Delivery for Nanomedicines.” FIP Centennial 2012, 8th Oct, 2012. (Amsterdam, Netherland)
  13. Harashima H. “Multifunctional Envelope-type Nano Device for Non-viral Gene Delivery.” IBS 2012　15th International Biotechnology Symposium and Exhibition, 17th September, 2012, (Korea)
  14. Yamada Y, Harashima H. “Mitochondrial delivery of bioactive molecules using Dual Function (DF)-MITO-Porter.” 39th Annual Meeting & Exposition of the Controlled Release Society, 15th-18th July, 2012. (Quebec city, Canada)
  15. Harashima H. “Multifunctional Envelope-type Nano Device for Non-viral Gene Delivery: Concept and Application for Nanomedicine.” 14th Asia Pacific Confederation of Chemical Engineering Congress, 23th February, 2012 (Singapore)
  16. Harashima H. “Multifunctional Envelope-type Nano Device for Non-viral Gene Delivery: Concept and Application for Nanomedicine.” International Symposium on Past, Present and Future of Molecular Pharmacokinetics, 16th-18th January, 2012 (Tokyo)
  17. Harashima H. “Multifunctional Envelope-type Nano Device for Non-viral Gene Delivery from Passive Targeting to Active Targeting.” The 19th Annual Meeting of the Japanese Vasculart Biology and Medicine Organization The 1st Asia-Pacific Vascular Biology Meeting, December 10, 2011 (Tokyo)
  18. Harashima H. “Multifunctional Envelope-type Nano Device for non-viral gene delivery: Concept and Application for Nanomedicine.” The 14th Hokkaido University – Seoul National University Joint Sympojium, 18th Nov, 2011 (Seoul, Korea)
  19. Kajimoto K. “Vascular Targeted Nanoparticulate System for Enhanced Therapy of Obesity.” The 14th Hokkaido University – Seoul National University Joint Sympojium, 18th Nov, 2011 (Seoul, Korea).
  20. Harashima H. “Multifunctional Envelope-type Nano Device for Non-viral Gene Delivery: Concept and Application for Nanomedicine.” Joint Meeting of the Austrian and German Pharmaceutical Sciences, 23th Sep, 2011 (Innsbruck, Austria)
  21. Harashima H. “Multifunctional Envelope-type Nano Device for Non-viral Gene Delivery.” The Smart Biomaterials for Gene Delivery, The 3rd Asian Biomaterials Congress, 16th Sep, 2011 (Busan, Korea)
  22. Harashima H. “Multifunctional Envelope-type Nano Device For non-viral gene delivery: Concept and application for Nanomedicine.” Medical Application of Nano Materials, The 14th Asian Chemical Congress, 10th Sep, 2011 (Bankok, Thailand)
  23. Harashima H. “Multifunctional Envelope-type Nano Device For non-viral gene delivery: Concept and application for Nanomedicine.” Joint Symposium with the Japanese Cancer Association, Trends of molecular & cell therapy for malignancies as translational research, The 17th Annual Meeting of JSGT, 16 Jul, 2011 (Hukuoka)
  24. Harashima H. “Controlled Intracellular trafficking of Non-viral Vectors.” Gene & Cell Therapy Around the Globe: A Showcase of Asia, The 14th Annual Meeting of ASGCT, 21st May, 2011 (Seattle, USA)
  25. Hatakeyama H. “Development of systemic siRNA delivery system: manipulation of intracellular trafficking.” The 13th Hokkaido University – Seoul National University Joint Symposium, 26th Nov, 2010 (Sapporo).
  26. Kajimoto K. “Nanoparticulate carrier system with peptide ligand for active targeting to vascular endothelium in fat tissue.” The 13th Hokkaido University – Seoul National University Joint Symposium, 26th Nov, 2010 (Sapporo).
  27. Akita H, Harashima H. “Control of intracellular trafficking of plasmid DNA and siRNA by multifunctional envelope-type nano device (MEND).” The 3rd international conference on mathematics and natural sciences (ICMNS2010), 23-25th Nov, 2010 (Bandung, Indonesia)
  28. Harashima H. “Multifunctional Envelope-type Nano Device for non-viral gene delivery.” Recent Trends in Gene and Drug Delivery. The 9th France – Japan DDS Symposium, 29th Sep, 2010 (Kumamoto)
  29. Harashima H. “Multifunctional Envelope-type Nano Device for non-viral gene delivery.” Symposium on Innovative Polymers for Controlled Delivery (SIPCD2010), 15th Sep, 2010 (Suzhou, China)
  30. Harashima H. “Multifunctional Envelope-type Nano Device for non-viral gene delivery: Concept and application for Nanomedicine.” The 4th International Symposium for Intelligent DDS, 6th May, 2010 (Seoul, Korea)
  31. Harashima H. “Multifunctional Envelope-type Nano Device for non-viral gene delivery: Concept and application for Nanomedicine.” The 7th Assiut University International Pharmaceutical Sciences Conference, 18th Mar, 2010 (Egypt)
  32. Harashima H. “Multifunctional envelope-type nano device for non-viral gene delivery: Concept and application for nanomedicine.” Asian Federation for Pharmaceutical Sciences 2009, 17th Oct, 2009 (Hakata)
  33. Harashima H. “Multifunctional envelope-type nano device for non-viral gene delivery: Concept and application of programmed packaging.” The 8th CVB2009, 1st Jul, 2009 (Sendai)

 

 

Presentation, international
  1. Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H, Harashima H. “Development of an in vivo Active siRNA Delivery System to Tumor Endothelial Cells using Cyclic RGD-modified Liposomal siRNA”, 9 th Annual Meeting of Oligonucleotide Therapeutics Society, 6th-8th, October, 2013 (Naples, Italy)
  2. Hyodo M, Miyabe H, Nakamura T, Sato Y, Hatakeyama, H, Harashima H. “Investigation of c-di-GMP MEND – a new class of adjuvant drug delivery system -”, 9 th Annual Meeting of Oligonucleotide Therapeutics Society, 6th-8th October, 2013 (Naples, Italy)
  3. Suemitsu E, Hayashi Y, Kajimoto K, Sato Y, Akhter A, Sakurai Y, Hatakeyama H, Hyodo M, Harashima H, “A new approach for innovative nanomedicine of type 2 diabetes in combination with DNA microarray and in vivo siRNA delivery.” 40th Annual Meeting & Exposition of the Controlled Release Society, 21th-24th, July,, 2013 (Honolulu, Hawaii, USA)
  4. Hossen MN, Kajimoto K, Akita H, Hyodo M, Hatashima H, “Effect of a nanoparticle-based multivalent targeted proapoptotic peptide on obesity.” 40th Annual Meeting & Exposition of the Controlled Release Society, 21th-24th, July,, 2013 (Honolulu, Hawaii, USA)
  5. Toriyabe N, Hayashi Y, Harashima H. “The new pH sensitive polycation improves the transfection activity of R8-nanoparticles by facilitating siRNA condensation” 72nd FIP World Congress 2012, 3rd-8th Oct, 2012. (Amsterdam, Netherlands)
  6. Hayashi Y, Kajimoto K, Sato Y, Suemitsu E, Akhter A, Sakurai Y, Hatakeyama H, Hyodo M, Kaji N, Baba Y, Harashima H. “An integrated strategy with DNA microarray and non-viral in vivo siRNA delivery to discover novel therapeutic targets for type 2 diabetes” 10th Annual discovery on target, 1st – 3rd, Oct, 2012. (Boston, USA)
  7. Hyodo M, Ara MN, Takaya Y, Harashima H. “Isolation of new DNA aptamers for pancreatic cancer cells.” IS3NA XX International Roundtable. 5th – 9th Aug, 2012 (Montreal, Canada).
  8. Tawaraya Y, Hyodo M, Yamada Y, Harashima H. “Investigation of RNA aptamers targeting mitochondria by mitochondria based SELEX.” IS3NA XX International Roundtable. 5th – 9th Aug, 2012 (Montreal, Canada).
  9. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. “Tumor Vasculature Targeted Size Controlled PEGylated Liposomal Delivery System to Treat Chemotherapy Resistant Renal Cell Carcinoma.” 39th Annual Meeting & Exposition of the Controlled Release Society. 15-18th Jul, 2012 (Quebec, Canada)
  10. Hatakeyama H, Takara K, Kibria G, Ohga N, Hida K, Harashima H. “Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.” 39th Annual Meeting & Exposition of the Controlled Release Society. 15-18th Jul, 2012 (Quebec, Canada)
  11. Sakurai Y, Sato Y, Hatakeyama H, Akita H, Hyodo M, Harashima H. “Confirming RNAi-mediated Gene Silencing in tumor by PEGylated siRNA-loaded liposome.” 39th Annual Meeting & Exposition of the Controlled Release Society. 15-18th Jul, 2012 (Quebec, Canada)
  12. Mizuno R, Hayashi Y, Khalil IA, Harashima H. “Gene therapy for LPS/D-GalN-induced hepatitis by octaarginine peptide-modified nanoparticles.” The 39th Annual Meeting & Exposition of the Controlled Release Society, 15-18th Jul, 2012. (Quebec, Canada)
  13. Noguchi Y, Hayashi Y, Harashima H. “In vitro / in vivo correlation analysis using siRNA-loaded lipid nanoparticles” The 39th Annual Meeting & Exposition of the Controlled Release Society, 15-18th Jul, 2012. (Quebec, Canada)
  14. Ara MN, Hyodo M, Ohga N, Hida K, Harashima H. “Development of a new DNA aptamer against primary cultured tumor endothelial cells by a cell-based SELEX method to discover a new drug delivery system.” AACR annual meeting 2012. 31th March – 4th April, 2012 (Chicago, Illinois, USA).
  15. Hayashi Y, Mizuno R, Yamauchi J, Khalil IA, Harashima H. “Octaarginine peptide-based nanoparticle system for liver-targeted nucleic acid delivery” The 9th International Symposium for Future Drug Discovery and Medical Care, 29-30th Sep, 2011. (Sapporo, Japan)
  16. Hatakeyama H, Yamamoto M, Hayashi Y, Kajimoto K, Akita H, Kaji N, Baba Y, Harashima H. “A DNA microarray-based analysis of the host response to a nonviral gene carrier: exploring CpG-dependent/independent mechanisms.” 7th annual meeting of the Oligonucleotide Therapeutics Society. 8-10th Sep, 2011 (Copenhagen, Denmark).
  17. Sakurai Y, Hatakeyama H, Sato Y, Akita H, Harashima H. “Endosomal Escape of liposomal siRNA via membrane fusion and in vivo delivery to tumor.” 7th annual meeting of the Oligonucleotide Therapeutics Society. 8-10th Sep, 2011 (Copenhagen, Denmark).
  18. Sato Y, Hatakeyama H, Sakurai Y, Hyodo M, Akita H, Harashima H. “In vivo siRNA delivery with pH-sensitive liposome.” 7th annual meeting of the Oligonucleotide Therapeutics Society. 8-10th Sep, 2011 (Copenhagen, Denmark).
  19. Hayashi Y, Mizuno R, Khalil IA, Harashima H. “Octaarginine- and pH Sensitive Fusogenic Peptide-Modified Nanoparticles for Liver Gene Delivery.” The 14th Annual Meeting of the American Society of Gene and Cell Therapy, 18-21th May, 2011. (Seattle, WA, USA)
  20. Toriyabe N, Hayashi Y, Hyodo M, Harashima H. “Synthesis and Evaluation of Stearylated Hyaluronic Acid Material for Active Liposomal Delivery to Liver Endothelial Cells.” The 14th Annual Meeting of the American Society of Gene and Cell Therapy, 18-21th May, 2011. (Seattle, WA, USA)
  21. Yamauchi J, Hayashi Y, Khalil IA, Akita H, Harashima H. “Cell Penetrating Peptide-Mediated Systemic siRNA Delivery to the Liver.” The 14th Annual Meeting of the American Society of Gene and Cell Therapy, 18-21th May, 2011. (Seattle, WA, USA)
  22. Kibria G, Hatakeyama H, Harashima H. “A new peptide motif present in protective antigen of anthrax toxin exerts its efficiency on cellular uptake of liposomes and application for dual-ligand system.” Pharmaceutical Sciences World Congress (PSWC)2010. 16th Nov, 2010 (New Orleans, USA).
  23. Kibria G, Hatakeyama H, Harashima H. “A new peptide motif present in protective antigen of anthrax toxin exerts its efficiency on cellular uptake of liposomes and application for dual-ligand system.” Pharmaceutical Sciences World Congress (PSWC)2010 Congress for Students and Postdoctoral Fellows. 13th Nov, 2010 (New Orleans, USA).
  24. Yamauchi J, Hayashi Y, Kajimoto K, Akita H, Harashima H. “The usefulness of multifunctional envelope-type nano device for gene delivery to the liver.” The 8th International Symposium for Future Drug Discovery and Medical Care, 1st-2nd Sep, 2010. (Sapporo, Japan)
  25. Takara K, Hatakeyama H, Ohga N, Hida K, Harashima H. “Design of dual-ligand-based liposomal delivery system comprising NGR motif and cell penetrating peptide.” 12th Liposome Research Days Conference. 4th Aug, 2010 (Vancouver, Canada).
  26. Hatakeyama H, Ito E, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H. “Development of siRNA-containing nanoparticles for in vitro and in vivo gene silencing in tumor by controlling intracellular trafficking.” 12th Liposome Research Days Conference. 4th Aug, 2010 (Vancouver, Canada).
  27. Hayashi Y, Yamauchi J, Akita H, Masuda T, Ukawa M, Konno T, Ishihara K, Harashima H. “Modification of biocompatible polymers and endosomal escape device can go up liver gene expression and prevent immune response.” International liposome research days & lipids liposomes & membrane biophysic, 4-8th Aug, 2010. (Vancouver, Canada)
  28. Yamauchi J, Hayashi Y, Kajimoto K, Akita H, Harashima H. “Comparison between a multifunctional envelope-type nano device and lipoplex to the liver.” International liposome research days & lipids liposomes & membrane biophysic, 4-8th Aug, 2010. (Vancouver, Canada)
  29. Sakurai Y, Hatakeyama H, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H. “A pH-sensitive fusogenic peptide modified siRNA-encapsulating nanoparticles exerts the gene silencing synergistically with tumor-specific cleavable PEG-lipid.” The 13th Annual Meeting of the American Society of Gene Therapy. 20th May, 2010 (Washington DC, USA).
  30. Hatakeyama H, Ito E, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H. “Application of siRNA-containing nanoparticles for in vitro and in vivo gene silencing in tumor by controlling intracellular trafficking.” The 13th Annual Meeting of the American Society of Gene Therapy. 20th May, 2010 (Washington DC, USA).
  31. Sato Y, Hatakeyama H, Harashima H. “Ornithine and tryptophan as an efficient polycation for siRNA delivery to tumor cells.” The 13th Annual Meeting of the American Society of Gene Therapy. 22th May, 2010 (Washington DC, USA).
  32. Hatakeyama H, Ito E, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H. “A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhanced the gene silencing of siRNA-containing nanoparticles in vitro and in vivo.” Joint Symposium of OTS-Antisense 2009. 3-6th Nov, 2009 (Fukuoka, Japan).
  33. Sakurai Y, Hatakeyama H, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H. “Development of efficient siRNA delivery system to tumor cells by combining octaarginine, GALA and enzymatically-cleavable PEG-lipid.” The Asian Federation for Pharmaceutical Sciences 2009. 15-18th Oct, 2009 (Fukuoka, Japan).